Variant Phenotype Annotation
证据URL
https://www.pharmgkb.org/variantAnnotation/1183703493
总结
CYP2D6 *4/*6 (assigned as poor metabolizer phenotype) is associated with increased AUC, Cmax and half-life time of fluvoxamine when treated with fluvoxamine in healthy individuals as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .